

## Viracta Therapeutics to Present at Upcoming Investor Conferences

San Diego, November 7, 2023 – [Viracta](#) Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Company's Management will participate in upcoming investor conferences in November.

Details on the conferences can be found below:

### **Stifel 2023 Healthcare Conference**

Presentation Date: Wednesday, November 15, 2023

Presentation Time: 10:20 – 10:50 AM ET

### **Piper Sandler 35<sup>th</sup> Annual Healthcare Conference**

Presentation Date: Tuesday, November 28, 2023

Presentation Time: 12:10 – 12:30 PM ET

### **6<sup>th</sup> Annual Evercore ISI HealthCONx Conference**

Presentation Date: Wednesday, November 29, 2023

Presentation Time: 3:25 – 3:45 PM ET

A live webcast of the presentation will be available on the Investors section of the Viracta website under "[Events and Webcasts](#)" and archived for 90 days.

### **About Viracta Therapeutics, Inc.**

Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory Epstein-Barr virus-positive (EBV<sup>+</sup>) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of patients with recurrent or metastatic EBV<sup>+</sup> nasopharyngeal carcinoma and other advanced EBV<sup>+</sup> solid tumors. Viracta is also pursuing the application of its "*Kick and Kill*" approach in other virus-related cancers.

For additional information please visit [www.viracta.com](http://www.viracta.com).

### **Investor Relations Contact:**

Ashleigh Barreto

Head of Investor Relations & Corporate Communications

Viracta Therapeutics, Inc.

[abarreto@viracta.com](mailto:abarreto@viracta.com)

SOURCE Viracta Therapeutics, Inc.

---

<https://viracta.investorroom.com/2023-11-07-Viracta-Therapeutics-to-Present-at-Upcoming-Investor-Conferences>